MedTrace Logo

ATAC - Bone Density Sub-Protocol

NCT00784940 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 308

Last updated 2009-04-27

No results posted yet for this study

Summary

To assess and quantify the changes in bone mineral density between the ARIMIDEX and ARIMIDEX plus NOLVADEX groups when compared to the NOLVADEX alone treatment group whilst receiving trial therapy.

Conditions

  • Bone Density

Interventions

DRUG

Anastrozole

1mg, orally, once daily

DRUG

Tamoxifen

20mg, orally, once daily

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-06-30
Primary Completion
2005-03-31
Completion
2007-04-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00784940 on ClinicalTrials.gov